Spirulina and Platelet Activation: GPIb-IX-V, PAR1/4, and TXA2 Signalling

Platelet Activation Receptors

Platelets are anucleate cells that monitor vascular integrity through a suite of surface receptors. Major activation receptors include: (1) PAR1 (F2R) and PAR4 (F2RL3), thrombin-cleaved GPCRs coupling to Gq (PLC-beta→IP3→Ca2+, DAG→PKC) and G12/13 (RhoA→Rho-kinase→cytoskeletal contraction); (2) P2Y12 (ADRA2A-like GPCR), ADP receptor coupling to Gi (adenylyl cyclase inhibition, reduced cAMP); (3) GPVI (FcR gamma-chain ITAM), collagen receptor activating Syk/LAT/PLC-gamma2; (4) TXA2 receptor (TP-alpha/TP-beta), thromboxane A2 GPCR amplifying platelet aggregation.

TXA2 Synthesis and Nrf2-COX2 Cross-talk

Activated platelets release arachidonic acid (AA) via cytosolic phospholipase A2 (cPLA2), which is then converted by COX-1 (PTGS1, constitutively expressed in platelets which lack nuclei and cannot induce COX-2) to PGH2, and then by thromboxane A synthase (TBXAS1) to TXA2. TXA2 activates TP receptors on the same platelet (amplification) and on smooth muscle (vasoconstriction). Spirulina's GLA reduces AA availability for cPLA2/COX-1; DGLA-derived PGE1 antagonises TP receptor signalling; and PCB reduces inflammatory COX-2 (relevant in nucleated cells contributing to the thrombotic microenvironment, not platelets themselves).

cAMP and cGMP: Anti-Aggregatory Second Messengers

Prostacyclin (PGI2) from endothelium binds IP receptor (PTGIR) on platelets, activating Gs-adenylyl cyclase and raising cAMP. PKA (cAMP-dependent kinase) phosphorylates and inhibits multiple platelet activation proteins: VASP Ser157 (marker of cAMP signalling), IP3R Ser1755 (reducing Ca2+ release), and GPIb (reducing von Willebrand factor binding). Similarly, NO from endothelium activates sGC, raising cGMP and activating PKG. Spirulina supports endothelial NO production (via arginine/eNOS coupling maintenance) and may preserve PGI2 synthesis (PCB reduces the oxidative inactivation of prostacyclin synthase at Tyr430 by peroxynitrite), sustaining both anti-aggregatory signals.

P2Y12 and ADP Pathway

ADP released from dense granules of activated platelets amplifies aggregation via P2Y12 (Gi coupling, inhibiting adenylyl cyclase) and P2Y1 (Gq coupling, Ca2+ mobilisation). P2Y12 is the target of clopidogrel (prodrug, CYP2C19-activated irreversible blocker) and ticagrelor (direct reversible blocker). Spirulina polysaccharides have been reported to reduce ADP-induced platelet aggregation in vitro through mechanisms including: (1) PGI2/cAMP elevation from endothelial support; (2) direct competition with ADP for purinergic sites; (3) reduction of P-selectin (CD62P) surface expression consistent with dense granule secretion suppression.

GPVI and Collagen Signalling

Collagen-exposed at sites of vascular injury activates platelet GPVI (associated with FcR gamma-chain ITAM), recruiting Src family kinases (Fyn, Lyn) that phosphorylate ITAM tyrosines, recruiting Syk. Syk phosphorylates LAT (linker for activation of T cells), assembling the PLC-gamma2-Btk-SLP76 signalosome. PLC-gamma2 generates DAG and IP3, activating PKC and intracellular Ca2+ release respectively. PKC-theta activates the integrin alphaIIbbeta3 (GPIIb/IIIa) to bind fibrinogen and form platelet aggregates. Spirulina spirulan polysaccharides demonstrate anticoagulant activity partly attributed to GPVI pathway modulation in ex vivo platelet studies.

Spirulina Clinical Antiplatelet Evidence

A small randomised trial (n=36) found spirulina supplementation (4.5 g/day, 3 months) reduced whole blood aggregation to ADP and collagen. Plasma thromboxane B2 (stable TXA2 metabolite) was also reduced. These findings are mechanistically consistent with the GLA/DGLA shift in eicosanoid profile, the cPLA2/AA substrate reduction, and endothelial NO/PGI2 preservation described above. The antiplatelet activity complements spirulina's other cardiovascular effects (LDL reduction, blood pressure modulation).